Liver drug study pulled before it even started
NCT ID NCT04244877
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if the antibiotic rifaximin could help people with liver cirrhosis who have a mild form of brain fog called covert hepatic encephalopathy, along with bacterial overgrowth in the gut. Researchers planned to give 40 patients rifaximin for eight weeks and test their thinking skills and gut function. However, the trial was withdrawn before enrolling anyone, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifaximin (Xifaxan) tablet
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.